Lipopolysaccharide stimulates the expression of interleukin-6 and nuclear factor kappa B receptor activator ligand in mouse MLO-Y4 osteoblasts

doi:10.12307/2022.608

Abstract

Abstract: BACKGROUND: Previous studies have confirmed that lipopolysaccharide could up-regulated the expression of interleukin-6, an inflammation-related cytokine, in mouse MLO-Y4 osteocytes, and interleukin-6 could further up-regulate the expression of receptor activator of nuclear factor κB ligand (RANKL), a factor related to osteoclastogenesis, in osteoblasts. PI3K/AKT signaling pathway is an important regulatory pathway in bone metabolism. Verifying whether this signaling pathway is involved in the production of inflammatory factors induced by lipopolysaccharides is greatly beneficial to studying the mechanism of bone resorption that is caused by bacterial inflammation.
OBJECTIVE: To verify whether PI3K/AKT signaling pathway is involved in the expression of interleukin-6 and RANKL in mouse MLO-Y4 osteocytes stimulated by lipopolysaccharides.
METHODS: MLO-Y4 osteoblasts were stimulated with 0 or 100 µg/L lipopolysaccharides for 1, 2, 4, 6, and 8 hours. Then the mRNA expressions of interleukin-6 and RANKL were detected by real-time quantitative polymerase chain reaction, and the protein expression of RANKL and p-AKT were detected by western blot. MLO-Y4 osteocytes in logarithmic growth was divided into seven groups: no treatment group (control group), 100 µg/L lipopolysaccharide group, 1 µmol/L PI3K inhibitor+100 µg/L lipopolysaccharide group, 2.5 µmol/L PI3K inhibitor+100 µg/L lipopolysaccharide group, 5 µmol/L PI3K inhibitor+100 µg/L lipopolysaccharide group, 10 µmol/L PI3K inhibitor+100 µg/L lipopolysaccharide group, 20 µmol/L PI3K inhibitor+100 µg/L lipopolysaccharide group. Real-time quantitative polymerase chain reaction was used to detect the mRNA expression of interleukin 6 and RANKL. MLO-Y4 osteocytes were divided into four groups: no treatment group (control group), 100 µg/L lipopolysaccharide group, dimethyl sulfoxide+100 µg/L lipopolysaccharide group, and 10 µmol/L PI3K inhibitor+100 µg/L lipopolysaccharide group. Real-time quantitative polymerase chain reaction was used to detect the mRNA expression of RANKL, and western blot was used to detect the protein expression of RANKL and p-AKT.
RESULTS AND CONCLUSION: After lipopolysaccharide stimulation, the mRNA expression of interleukin-6 and RANKL in osteocytes was increased first and then decreased; however, the mRNA expression levels were higher than those in the control group at each time point (P < 0.05). After lipopolysaccharide stimulation, the protein expression of RANKL and p-AKT in osteocytes was significantly higher than that in the control group (P < 0.05) at each time point, although the protein expression in lipopolysaccharide groups was increased first and then decreased. PI3K inhibitor of 1-10 µmol/L could decrease the mRNA expression of interleukin 6 and RANKL in lipopolysaccharide-induced osteocytes in a concentration-dependent manner, while 20 and 10 µmol/L PI3K inhibitor showed similar effects. Both dimethyl sulfoxide and PI3K inhibitors could inhibit the increase in the protein and mRNA expression of RANKL and the protein expression of p-AKT in osteocytes induced by lipopolysaccharide. Furthermore, PI3K inhibitor showed the better inhibitory effect. These results indicate that lipopolysaccharide stimulates the expression of interleukin-6 and RANKL in mouse MLO-Y4 osteocytes through the PI3K/AKT signaling pathway.

Key words: osteocyte, interleukin-6, lipopolysaccharide, PI3K/AKT, receptor activator of nuclear factor-κB ligand, bone resorption, phosphorylation, PI3K inhibitor

CLC Number:

Liu Qiqi, Liu Min, Yang Jian, Yu Ke. Lipopolysaccharide stimulates the expression of interleukin-6 and nuclear factor kappa B receptor activator ligand in mouse MLO-Y4 osteoblasts[J]. Chinese Journal of Tissue Engineering Research, 2022, 26(20): 3121-3126.

Figures/Tables 6

References

[1] BRONZATO JD, DAVIDIAN MES, DE CASTRO M, et al. Bacteria and virulence factors in periapical lesions associated with teeth following primary and secondary root canal treatment. Int Endod J. 2021;54(5):660-671.
[2] 刘大勇,王梅蕊,兰玲玲,等.脂多糖干预卵巢切除小鼠骨髓间充质干细胞的成骨分化能力[J].中国组织工程研究,2014,18(14):2219-2225.
[3] 余科,吴湘楠,刘文佳,等. LPS刺激小鼠骨细胞RANKL/OPG和IL-6表达的实验研究[J].口腔医学研究,2016(3):220-223.
[4] YU K, MA Y, LI X, et al. Lipopolysaccharide increases IL-6 secretion via activation of the ERK1/2 signaling pathway to up-regulate RANKL gene expression in MLO-Y4 cells. Cell Biol Int. 2017;41(1):84-92.
[5] GALARRAGA-VINUEZA ME, DOHLE E, RAMANAUSKAITE A, et al. Anti-inflammatory and macrophage polarization effects of Cranberry Proanthocyanidins (PACs) for periodontal and peri-implant disease therapy. J Periodontal Res. 2020;55(6):821-829.
[6] LI G, LIU Y, MENG F, et al. LncRNA MEG3 inhibits rheumatoid arthritis through miR-141 and inactivation of AKT/mTOR signalling pathway. J Cell Mol Med. 2019; 23(10):7116-7120.
[7] ZHAO X, ALQWBANI M, LUO Y, et al. Glucocorticoids decreased Cx43 expression in osteonecrosis of femoral head: The effect on proliferation and osteogenic differentiation of rat BMSCs. J Cell Mol Med. 2021;25(1):484-498.
[8] KITAURA H, MARAHLEH A, OHORI F, et al. Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption. Int J Mol Sci. 2020;21(14):5169.
[9] FENG W, GUO J, LI M. RANKL-independent modulation of osteoclastogenesis. J Oral Biosci. 2019;61(1):16-21.
[10] AMIN N, BOCCARDI V, TAGHIZADEH M, et al. Probiotics and bone disorders: the role of RANKL/RANK/OPG pathway. Aging Clin Exp Res. 2020;32(3):363-371.
[11] Martin TJ, Sims NA. RANKL/OPG; Critical role in bone physiology. Rev Endocr Metab Disord. 2015;16(2):131-139.
[12] JIANG J, JIA Y, LU X, et al. Vitexin suppresses RANKL-induced osteoclastogenesis and prevents lipopolysaccharide (LPS)-induced osteolysis. J Cell Physiol. 2019; 234(10):17549-17560.
[13] FANG L, WANG KK, HUANG Q, et al. Nucleolin Mediates LPS-induced Expression of Inflammatory Mediators and Activation of Signaling Pathways. Curr Med Sci. 2020;40(4):646-653.
[14] CHAE BS. Pretreatment of Low-Dose and Super-Low-Dose LPS on the Production of In Vitro LPS-Induced Inflammatory Mediators. Toxicol Res. 2018;34(1):65-73.
[15] LEE GL, YEH CC, WU JY, et al. TLR2 Promotes Vascular Smooth Muscle Cell Chondrogenic Differentiation and Consequent Calcification via the Concerted Actions of Osteoprotegerin Suppression and IL-6-Mediated RANKL Induction. Arterioscler Thromb Vasc Biol. 2019;39(3):432-445.
[16] KIM HJ, KIM HJ, CHOI Y, et al. Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis. Int J Mol Sci. 2019;20(6):1467.
[17] MCGREGOR NE, MURAT M, ELANGO J, et al. IL-6 exhibits both cis- and trans-signaling in osteocytes and osteoblasts, but only trans-signaling promotes bone formation and osteoclastogenesis. J Biol Chem. 2019;294(19):7850-7863.
[18] BEZERRA MÉS, BARBERINO RS, MENEZES VG, et al. Insulin-like growth factor-1 (IGF-1) promotes primordial follicle growth and reduces DNA fragmentation through the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) signalling pathway. Reprod Fertil Dev. 2018;30(11):1503-1513.
[19] DENG S, DAI G, CHEN S, et al. Dexamethasone induces osteoblast apoptosis through ROS-PI3K/AKT/GSK3β signaling pathway. Biomed Pharmacother. 2019;110:602-608.
[20] MA Y, RAN D, ZHAO H, et al. Cadmium exposure triggers osteoporosis in duck via P2X7/PI3K/AKT-mediated osteoblast and osteoclast differentiation. Sci Total Environ. 2021;750:141638.
[21] DA Y, MOU Y, WANG M, et al. Mechanical stress promotes biological functions of C2C12 myoblasts by activating PI3K/AKT/mTOR signaling pathway. Mol Med Rep. 2020;21(1):470-477.
[22] SONG F, WANG Y, JIANG D, et al. Cyclic Compressive Stress Regulates Apoptosis in Rat Osteoblasts: Involvement of PI3K/Akt and JNK MAPK Signaling Pathways. PLoS One. 2016;11(11):e0165845.
[23] LI ST, DAI Q, ZHANG SX, et al. Ulinastatin attenuates LPS-induced inflammation in mouse macrophage RAW264.7 cells by inhibiting the JNK/NF-κB signaling pathway and activating the PI3K/Akt/Nrf2 pathway. Acta Pharmacol Sin. 2018; 39(8):1294-1304.
[24] ZHONG Z, CHEN A, FA Z, et al. Bone marrow mesenchymal stem cells upregulate PI3K/AKT pathway and down-regulate NF-κB pathway by secreting glial cell-derived neurotrophic factors to regulate microglial polarization and alleviate deafferentation pain in rats. Neurobiol Dis. 2020;143:104945.
[25] PROSSOMARITI A, PIAZZI G, ALQUATI C, et al. Are Wnt/β-Catenin and PI3K/AKT/mTORC1 Distinct Pathways in Colorectal Cancer? Cell Mol Gastroenterol Hepatol. 2020;10(3):491-506.
[26] YAN L, LU L, HU F, et al. Piceatannol attenuates RANKL-induced osteoclast differentiation and bone resorption by suppressing MAPK, NF-κB and AKT signalling pathways and promotes Caspase3-mediated apoptosis of mature osteoclasts. R Soc Open Sci. 2019;6(6):190360.
[27] BONEWALD LF. Establishment and characterization of an osteocyte-like cell line, MLO-Y4. J Bone Miner Metab. 1999;17(1): 61-65.
[28] LIN CN, DING SJ, CHEN CC. Synergistic Photoantimicrobial Chemotherapy of Methylene Blue-Encapsulated Chitosan on Biofilm-Contaminated Titanium. Pharmaceuticals (Basel). 2021;14(4):346.
[29] DOUGALL WC, GLACCUM M, CHARRIER K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999;13(18):2412-2424.
[30] MARAHLEH A, KITAURA H, OHORI F, et al. TNF-α Directly Enhances Osteocyte RANKL Expression and Promotes Osteoclast Formation. Front Immunol. 2019;10: 2925.
[31] KIM HN, XIONG J, MACLEOD RS, et al. Osteocyte RANKL is required for cortical bone loss with age and is induced by senescence. JCI Insight. 2020;5(19):e138815.
[32] UCHIBORI S, SEKIYA T, SATO T, et al. Suppression of tooth movement-induced sclerostin expression using β-adrenergic receptor blockers. Oral Dis. 2020;26(3): 621-629.
[33] ALQRANEI MS, CHELLAIAH MA. Osteoclastogenesis in periodontal diseases: Possible mediators and mechanisms. J Oral Biosci. 2020;62(2):123-130.
[34] TERAMACHI J, INAGAKI Y, SHINOHARA H, et al. PKR regulates LPS-induced osteoclast formation and bone destruction in vitro and in vivo. Oral Dis. 2017; 23(2):181-188.
[35] MENDOZA MC, ER EE, BLENIS J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36(6):320-328.
[36] EVANGELISTI C, CHIARINI F, CAPPELLINI A, et al. Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia. J Cell Physiol. 2020;235(6):5413-5428.
[37] DE SANTIS MC, GULLUNI F, CAMPA CC, et al. Targeting PI3K signaling in cancer: Challenges and advances. Biochim Biophys Acta Rev Cancer. 2019;1871(2):361-366.
[38] JOHNSON GE, IVANOV VN, HEI TK. Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival. Apoptosis. 2008;13(6):790-802.
[39] XIE Y, SHI X, SHENG K, et al. PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia (Review). Mol Med Rep. 2019;19(2):783-791.
[40] SUN K, LUO J, GUO J, et al. The PI3K/AKT/mTOR signaling pathway in osteoarthritis: a narrative review. Osteoarthritis Cartilage. 2020;28(4):400-409.
[41] MANNING BD, TOKER A. AKT/PKB Signaling: Navigating the Network. Cell. 2017; 169(3):381-405.
[42] CHEN H, ZHOU L, WU X, et al. The PI3K/AKT pathway in the pathogenesis of prostate cancer. Front Biosci (Landmark Ed). 2016;21:1084-1091.
[43] BAI L, GAO J, WEI F, et al. Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes. Front Pharmacol. 2018;9:423.
[44] HOARE A, SOTO C, ROJAS-CELIS V, et al. Chronic Inflammation as a Link between Periodontitis and Carcinogenesis. Mediators Inflamm. 2019;2019:1029857.